UNITY Biotechnology hosting virtual event to discuss positive Phase 2b ASPIRE study results.

From GlobeNewswire: 2025-03-23 16:00:00

UNITY Biotechnology, Inc. will host a virtual investor event on March 24th to review Phase 2b ASPIRE study results for UBX1325 in patients with DME. The investigational compound UBX1325 showed promising results in improving long-term visual outcomes. UBX1325 is designed to eliminate senescent cells in retinal tissue, potentially transforming outcomes for patients with retinal disease. UNITY is focused on developing therapeutics to slow, halt, or reverse age-related diseases, with a goal of improving real-world outcomes for patients. For more information, visit www.unitybiotechnology.com.



Read more at GlobeNewswire: UNITY Biotechnology to Host Virtual Investor Event to